Clinical trials: Advan'ce'd
Advan'ce'd, Advanced
IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer
This study is for patients with advanced or metastatic gastric cancer whose disease has worsened after first-line systemic therapy.
- Trial name
- NCT07361991
- Testing
- IBI363, Bevacizumab, Nab-paclitaxel
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University